DHGWA
CORT icon

Dixon Hughes Goodman Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$23K Hold
1,000
– – 0.01% 415
2021
Q4 		$20K Buy
+1,000
New +$20.3K 0.01% 372

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's CORT Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors held its Corcept Therapeutics (CORT) position steady in Q1 2022 at 1,000 shares worth $23K. The position accounts for 0.01% of the portfolio, ranked #415.

Dixon Hughes Goodman Wealth Advisors first reported a position in CORT in Q4 2021 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

  • Dixon Hughes Goodman Wealth Advisors held 1,000 shares of Corcept Therapeutics worth $23K as of Q1 2022.
  • Dixon Hughes Goodman Wealth Advisors left its Corcept Therapeutics share count unchanged in Q1 2022.
  • Corcept Therapeutics made up 0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #415 holding.
  • Dixon Hughes Goodman Wealth Advisors first reported a position in Corcept Therapeutics in Q4 2021 and has held it in 2 quarters since.
  • 228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.